A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
for Crohn Disease
Drug: Risankizumab
17 locations incl. Dothan
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT07499232·Phase 3·Recruiting